tbuckley/cabot-search huggingface dataset:
Dabigatran Is Associated with a Significantly Lower Risk of Abnormal Uterine Bleeding Than Warfarin in Female Patients of Childbearing Age with Venous Thromboembolism
Authors: Melanie Ferreira, Frederikus A Klok, Martin Feuring, Mandy Fraessdorf, Jörg Kreuzer, Menno V Huisman
Journal: Blood (2016)
Realising the potential of mHealth to improve asthma and allergy care: how to shape the future
Authors: Jean Bousquet, Niels H. Chavannes, Nick Guldemond, Tari Haahtela, Peter W. Hellings, Aziz Sheikh
Journal: European Respiratory Journal (2017)

mHealth (mobile health) refers to the use of mobile and wireless devices in the support of healthcare delivery and improvement of health outcomes. mHealth has evolved from eHealth (electronic health), the use of information and communication technology (ICT) for health services and information transfer. According to the World Health Organization \[1], mHealth "has the potential to transform the face of health service delivery across the globe. A powerful combination of factors is driving this change. These include rapid advances in mobile technologies and applications, a rise in new opportunities for the integration of mobile health into existing mHealth services, and the continued growth in coverage of mobile cellular networks." The potential applications and benefits of mHealth are extensive and expanding [2\] (table 1). Many of these tools can be applied to asthma and allergies. mHealth is promising but the human factors for its design, development and evaluation need to be considered <http://ow.ly/cEhN30an6TK>
Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types
Authors: Tiziana D'Agaro, Tamara Bittolo, Vanessa Bravin, Antonella Zucchetto, Michele Dal Bo, Francesca Rossi, Federico Pozzo, Annalisa Chiarenza, Giovanni D'Arena, Gabriele Pozzato, Francesco Zaja, Davide Rossi, Francesco Di Raimondo, Gianluca Gaidano, Giovanni Del Poeta, Pietro Bulian, Valter Gattei, Riccardo Bomben
Journal: Blood (2016)
Mosaic Analysis with Double Markers Reveals Distinct Sequential Functions of Lgl1 in Neural Stem Cells
Authors: Robert Beattie, Maria Pia Postiglione, Laura E. Burnett, Susanne Laukoter, Carmen Streicher, Florian M. Pauler, Guanxi Xiao, Olga Klezovitch, Valeri Vasioukhin, Troy H. Ghashghaei, Simon Hippenmeyer
Journal: Neuron (2017)
Chemotherapeutic responses and cell migration rates in human colon carcinoma cells and their lymph node metastatic derivatives
Authors: C Lahiff, J O'Sullivan, D Fennelly, K Sheahan, H Mulcahy, J Hyland, D O'Donoghue
Journal: Endoscopy (2005)

Aims: Standard adjuvant treatment of colorectal cancer (CRC) is fluorouracil plus leucovorin (FL) and oxaliplatin improves the efficacy of this combination. We compared drug sensitivities and cell migration rates in models of early (SW480 cells) and advanced staged CRC (SW620 cells).
Surgical Site Infection Prevention—What We Know and What We Do Not Know
Authors: Pamela A. Lipsett
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
Authors: Cordula A. Jilg, Vanessa Drendel, H. Christian Rischke, Teresa Beck, Werner Vach, Kathrin Schaal, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T. Meyer
Journal: Theranostics (2017)

Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels.Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND).Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa.Design, setting and participants: 30 patients with the suspicion of exclusively nodal PCa-relapse after primary therapy underwent a template pelvic and/or retroperitoneal salvage-LND after whole body 68-Ga-PSMA-PET/CT.The diagnostic accuracy of PET/CT was evaluated in comparison to the histopathology of 965 resected lymph nodes (LN) dissected from 68 main regions (pelvic left/right, retroperitoneal) and 289 subregions (common iliac, external iliac, obturator, internal iliac, presacral, aortic-bifurcation, aortal, caval).LNM and tumor deposits in LNM were measured bidimensionally in the histopathology.PSMA-expression was analyzed by immunohistochemistry in LNM.Results: LNM were present in 11.4% of the resected LN (110/965) resulting in 45 positive main regions and 85 positive subregions.PET/CT was true positive in 41 main regions and 69 subregions.Three PET-negative main regions and 16 PET-negative subregions finally contained LNM, the majority of these false negative subregions (13/16) were in neighboring regions of true-positive subregions.Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were: main region-based 93.2%, 100%, 100%, 88.9% and 95.6%, subregion-based 81.2%, 99.5%, 98.6%, 92.7 and 94.1%.Median short diameters of tumor deposits in LNM resected from false-negative subregions (1.3 mm) were significantly smaller than in LNM removed from true-positive subregions (5.5 mm, p<0.0001).Based on anatomical subregions containing just one LNM, the necessary short diameter of tumor deposits in LNM required to reach a detection rate of 50% and 90% was estimated to be ≥ 2.3 mm and ≥ 4.5 mm, respectively. Conclusion:In men with biochemical PCa-relapse and positive PSMA-PET/CT, PET/CT detects metastatic affected anatomical regions with high accuracy at a main region and at a subregion-level.If the decision for salvage-LND is prompted by a positive PSMA-PET/CT, the size of metastases is crucial for accurate detection of affected regions.All LNM showed a clear PSMA-expression in the immunohistochemistry.Further studies need to investigate how to translate the high anatomical correlation observed between PET/CT and surgical findings into optimal approaches for target salvage-LND.
A phase II clinical trial of neoadjuvant therapy with zoledronic acid for operable breast cancer.
Authors: Yoshie Nakayama, Shunji Takahashi, Yoshinori Ito
Journal: Journal of Clinical Oncology (2013)

e22027 Background: The neoadjuvant use of bisphosphonates has been reported to increase rates of pathological response in patients with operable breast cancer. We conducted a study to determine whether treatment with zoledronic acid (ZOL) would improve outcomes in such patients when it was added to standard neoadjuvant chemotherapy (NAC). Methods: From April 2010 to June 2012, 30 patients with HER2-negative operable breast cancer were eligible for the study. The patients received NAC (4 cycles of CEF: intravenous epirubicin 100mg/m 2 , cyclophosphamide 500mg/m 2 , and fluorouracil 500mg/m 2 on day 1, then 12 cycles of weekly paclitaxel 80mg/m 2 ) with ZOL. The ZOL was administered after each cycle of NAC in a 4-mg dose by intravenous infusion every 3 to 4 weeks. The primary end point of the study was pathological response (pPR) rate. The secondary end points were pathological complete response (pCR) rate, adverse effects (AEs) and the changes in the numbers of disseminated tumor cells (DTC), circulating tumor cells (CTC), and circulating endothelial cells (CEC). We evaluated the efficacy and safety of ZOL in the NAC in patients by use of Fisher’s exact test. Results: 29 patients completed surgery after NAC, and pathological analyses and the numbers of CTC and CEC were assessed. Two patients had progressive disease during NAC, with brain metastasis and bone metastasis, respectively. The pPR rate, pCR rate, was 31.0%, 10.4%, respectively. CTC were detected in 3 patients at baseline, and CTC had changed to positive in one patient in D15 of the first cycle, then after NAC, all four patients changed to negative. CTC were negative in two patients at baseline, but after NAC, changed to positive. There were no factors associated with the change rates of CTC. CEC after NAC increased from baseline significantly (p&lt;0.001). The increase rates of CEC were not significantly different among premenopausal and postmenopausal, PR and non-PR, and luminal and triple negative patients. There were no severe AEs associated with ZOL to discontinue treatment. Conclusions: These data suggested ZOL in combination with NAC might not have a significant direct anti-tumor effect. Change of CEC would be a biomarker for NAC, but further analyses would be necessary. Clinical trial information: 000003498.
The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003
Authors: Claire Schwab, Amir Enshaei, Kathryn G. Roberts, Lisa J. Russell, Richard C Harvey, I-Ming L. Chen, Cheryl L. Willman, Charles Mullighan, Ajay J. Vora, Anthony V. Moorman, Christine Harrison
Journal: Blood (2016)
A Novel Single Chain Recombinant Factor VIII Fc Fusion Protein Is Active In Vitro and Fully Efficacious in An In Vivo Hema Mouse Bleeding Model
Authors: Yang Buyue, Tongyao Liu, Thomas Reidy, Susannah Patarroyo-White, George D Kamphaus, Mark Slein, Glenn F Pierce, Jurg M Sommer, Robert Peters
Journal: Blood (2011)
Evaluation of changes in the HR status and Her2 expression following neoadjuvant chemotherapy
Authors: C.R. Ponce, F.A. Colo, M. Maino, V.Y. Fabiano, C.M. Loza, M. Amat, A. Nervo, V. Costanzo, J.B. Loza, R. Chacon
Journal: Annals of Oncology (2017)
An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
Authors: Eddy Fan, Lorenzo Del Sorbo, Ewan C. Goligher, Carol L. Hodgson, Laveena Munshi, Allan J. Walkey, Neill K. J. Adhikari, Marcelo B. P. Amato, Richard Branson, Roy G. Brower, Niall D. Ferguson, Ognjen Gajic, Luciano Gattinoni, Dean Hess, Jordi Mancebo, Maureen O. Meade, Daniel F. McAuley, Antonio Pesenti, V. Marco Ranieri, Gordon D. Rubenfeld, Eileen Rubin, Maureen Seckel, Arthur S. Slutsky, Daniel Talmor, B. Taylor Thompson, Hannah Wunsch, Elizabeth Uleryk, Jan Brozek, Laurent J. Brochard
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsRecommendations for Speci...ConclusionsReferencesCITING ARTICLES
Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial
Authors: L.S. Lindström, C. Yau, K. Czene, C. Thompson, N. Yu, B. Nordenskjöld, O. Stål, C.C. Benz, T. Fornander, A.D. Borowsky, L. Esserman
Journal: Annals of Oncology (2017)
Allogeneic Hematopoietic Stem Cell Transplant with Ablative Conditioning Is Associated with Favorable Outcomes in Patients with Mixed Phenotype Acute Leukemia
Authors: Bartlomiej M Getta, Junting Zheng, Martin S. Tallman, Jae H. Park, Eytan M. Stein, Mikhail Roshal, Esperanza B. Papadopoulos, Nancy A. Kernan, Peter G. Steinherz, Richard J. O'Reilly, Miguel-Angel Perales, Sergio A. Giralt, Brian C. Shaffer
Journal: Blood (2016)
Using primary patient data to identify the symptoms of brain metastases to develop a patient-reported outcome measure.
Authors: Kathryn Eilene Lasch, Kristina Fitzgerald, Arijit Ganguli, Vijayveer Bonthapally, Farrah Pompilus, Laure Delbecque, Saurabh Ray
Journal: Journal of Clinical Oncology (2012)

e12515 Background: Increasingly, there has been a public call for direct patient input into the development of patient reported outcome (PRO) measures of treatment benefit in adult oncology clinical trials. Patient involvement is especially important in conditions where there is poor prognosis and comparative treatment benefit is minimal with standard outcome measures such as overall or progression free survival. To develop a PRO instrument specifically for patients with brain metastases (BM), this study interviewed patients in this population and also reviewed the clinical literature to identify the signs and symptoms relevant to BM. Methods: A literature search was performed inMEDLINE for articles published between 2000 and 2010. Individual in-depth interviews were conducted with 19 patients with BM using open-ended questions to elicit the most frequent and the most bothersome symptoms. Patient inclusion criteria included a diagnosis of BM and being eligible for whole brain radiotherapy. Results: The literature review identified the following symptoms as important: intracranial pressure symptoms (e.g., headache, nausea, vomiting), seizures, and focal neurological symptoms (e.g., paralysis, mental status changes, memory, motor loss/weakness, visual loss/changes). The most frequent symptoms reported by patients in the interviews were: headache (74%), memory loss (63%), vision problems (58%), loss of balance (53%), and physical weakness (53%). Also, the patient interviews identified the following as most bothersome: headache (32%) and vision problems (21%). The patients reported additional concepts not identified in the literature review, including pain, fear, falling, fainting, and difficulty reading. Some symptoms or signs identified in the literature were not mentioned by patients during the interviews such as intracranial hypertension and hemorrhage. Conclusions: Although there was considerable overlap among patient and literature reports, including patient input broadened the comprehensiveness of potential symptoms. The results suggest the added value of collecting direct, primary patient data when developing measures to assess benefits of treatment in BM patients.
A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends.
Authors: Jacques Raphael, Thivaher Paramsothy, Justin Lee, Sonal Gandhi
Journal: Journal of Clinical Oncology (2015)

1043 Background: Progression during neoadjuvant therapy (NAT) for LABC is uncommon. However, these patients often do poorly, and salvage treatment (ST) options are varied. Predictors of resistance or response to ST are not well defined. The goal of this study was to establish the characteristics of LABC patients requiring ST and potential predictors of response or progression after ST. Methods: A retrospective review was conducted using our LABC database. Survival outcomes were estimated using Kaplan-Meier. Fisher’s exact test was used to estimate the probability of progression after ST. PFS1 represents the time between diagnosis and first progression (on NAT) and PFS2 the time between the first progression and the second progression (after ST), or the date of last follow up. Results: Eighteen patients out of 232 (8%) progressed on primary NAT. Median follow up was 23 months and the median age 51. The majority (72%) of these patients had T3/T4 disease and 56% were also N1. Tumors were mainly ductal carcinoma (89%), grade 3 (78%) and 72% had triple negative receptor phenotype (TN). Most patients (94%) had local tumor progression alone; the most commonly used ST (56%) was concurrent radiation and cisplatin (RT/CT); 69% of the TN patients had RT/CT. 93% of the patients had a clinical response to ST and 72% had mastectomy. One patient (TN) had a complete pathologic response (pCR) on surgery after RT/CT, and 10 patients (56%) had a recurrence after ST. PFS1 and PFS2 were 4.2 and 29 months respectively. Median overall survival for all patients was 37.3 months. Initial tumor size was the only variable predictive of progression after ST (p= 0.03). Patients who received concurrent RT/CT had a trend towards better PFS2 (p= 0.08). Conclusions: In this patient cohort, progression on NAT was comparable to the literature. Most tumors were TN and of these almost 70% received RT/CT as ST. These patients had a trend towards improved progression free survival after ST; one patient had a pCR. Ongoing work in this area is imperative; effective ST can have a significant impact on delaying disease progression. ST with RT/CT should especially be investigated further for TN LABC progressing on NAT.
Ocular Graft-Versus Host Disease Prevention with Topical Cyclosporine in Non-Myeloablative Allogeneic Stem Cell Transplant
Authors: Rosa Elena Lozano-Morales, Alberto Vázquez-Mellado de Larracoechea, Olga Cantu-Rodriguez, Juan Luis Gonzalez-Treviño, Perla Rocío Colunga-Pedraza, Miguel Angel Herrera-Rojas, Monica Sánchez-Cárdenas, David Martínez-Garza, Daniela Michelle Pérez-Garza, David Gomez-Almaguer
Journal: Blood (2016)
Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling
Authors: Rachid Berair, Ruth Hartley, Vijay Mistry, Ajay Sheshadri, Sumit Gupta, Amisha Singapuri, Sherif Gonem, Richard P. Marshall, Ana R. Sousa, Aarti Shikotra, Richard Kay, Andrew Wardlaw, Peter Bradding, Salman Siddiqui, Mario Castro, Christopher E. Brightling
Journal: European Respiratory Journal (2017)

Airway remodelling in asthma remains poorly understood. This study aimed to determine the association of airway remodelling measured on bronchial biopsies with 1) lung function impairment and 2) thoracic quantitative computed tomography (QCT)-derived morphometry and densitometry measures of proximal airway remodelling and air trapping. Subjects were recruited from a single centre. Bronchial biopsy remodelling features that were the strongest predictors of lung function impairment and QCT-derived proximal airway morphometry and air trapping markers were determined by stepwise multiple regression. The best predictor of air trapping was validated in an independent replication group. Airway smooth muscle % was the only predictor of post-bronchodilator forced expiratory volume in 1 s (FEV 1 ) % pred, while both airway smooth muscle % and vascularity were predictors of FEV 1 /forced vital capacity. Epithelial thickness and airway smooth muscle % were predictors of mean segmental bronchial luminal area (R 2 =0.12; p=0.02 and R 2 =0.12; p=0.015), whereas epithelial thickness was the only predictor of wall area % (R 2 =0.13; p=0.018). Vascularity was the only significant predictor of air trapping (R 2 =0.24; p=0.001), which was validated in the replication group (R 2 =0.19; p=0.031). In asthma, airway smooth muscle content and vascularity were both associated with airflow obstruction. QCT-derived proximal airway morphometry was most strongly associated with epithelial thickness and airway smooth muscle content, whereas air trapping was related to vascularity.
Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).
Authors: Saifuddin M. Kasubhai, Johanna C. Bendell, Mark Kozloff, Amy V. Kapp, Avi Ashkenazi, Stephanie Royer-Joo, Chia C. Portera
Journal: Journal of Clinical Oncology (2012)

3543 Background: Dulanermin is a recombinant soluble human Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) that activates apoptotic pathways by binding to the pro-apoptotic death receptors DR4 and 5. This is the final update of the study assessing the safety of dulanermin combined with FOLFIRI (± BV) in previously treated mCRC pts. Methods: This was a multicenter, open-label, dose-escalation and cohort expansion study. Dulanermin was administered intravenously in 14-day cycles on Days 1, 2 and 3 at 9 mg/kg or 18 mg/kg, with FOLFIRI (+ BV in pts not previously treated with BV) on Day 1. Dose-limiting toxicity (DLT) was assessed through 2 cycles (28 days). Adverse events (AE) were recorded through all cycles. Response was assessed with RECIST (v1.0). Results: A total of 27 pts received 1-48 cycles (median 10) of dulanermin with FOLFIRI (1 pt received BV). No DLTs were reported and no relationship between dulanermin dose level and AE incidence or severity was detected. The most frequent AEs reported as dulanermin-related were fatigue (37%), anemia (19%), diarrhea, nausea, stomatitis, and weight decreased (15% each). The most frequent Grade ≥3 AEs reported as dulanermin-related were fatigue (15%), anemia, febrile neutropenia and vomiting (7% each). Serious AEs reported as dulanermin-related included: vomiting, dehydration, and febrile neutropenia (1 pt each). Some of these events were reported as related to dulanermin and other study drugs. One pt died on study due to disease progression. Other reasons for discontinuation of study treatment included disease progression (21 pts, 78%), and physician’s decision and pt’s decision (2 pts each, 7%). One pt is still receiving treatment. Among the 27 pts, best responses included 6 (22%) partial responses (5 confirmed, 1 unconfirmed), 17 (63%) stable disease, 3 (11%) progressive disease and 1 (4%) pt with no on-study tumor assessment. Conclusions: The addition of dulanermin to FOLFIRI (± BV) was well tolerated in previously treated mCRC pts. AEs were similar to those previously reported for the chemotherapy alone. Tumor responses were consistent with treatment response to FOLFIRI in this patient population.
Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial
Authors: J. Raoul, A. Craxi, C. Porta, G. Lentini, A. Nadel, D. Voliotis, J. Bruix, J. M. Llovet
Journal: Journal of Clinical Oncology (2009)

e15547 Background: Results from the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, a multinational, randomized, placebo-controlled, phase III trial, demonstrated that sorafenib is effective and safe for patients with advanced HCC (Llovet et al, N Engl J Med, 2008). As lymph nodes are among the most common sites of metastasis in patients with HCC, we performed subset analyses to evaluate the efficacy and safety of sorafenib in patients with or without lymph node metastases at baseline. Methods: Patients (N=602) with advanced, unresectable, measurable HCC, ECOG PS 0–2, Child-Pugh class A, and no prior systemic therapy for HCC were randomized 1:1 to receive either sorafenib 400 mg BID or placebo. End points included overall survival (OS), disease-control rate (DCR; defined as complete/partial response or stable disease by RECIST, maintained for ≥28 d from first demonstration of response), time to progression (TTP), and safety. Results: Median TTP, OS, and DCR by subset are shown in the table. The incidence of grade 3/4 drug-related adverse events across subgroups was consistent with that reported for the overall population. The most common grade 3/4 adverse events in the sorafenib populations were hand-foot skin reaction and diarrhea. Conclusions: Sorafenib prolonged OS and TTP in patients with advanced HCC, whether or not lymph node metastases were present at baseline. The safety profile of sorafenib in patients with lymph node metastases was comparable with that for the overall study population. [Table: see text] [Table: see text]